Methotrexate | Therapeutic | Drugs of Abuse | Research Samples

Discovery Life Sciences Therapeutic Drugs of Abuse Research Samples | Order Online with Immediate Overnight Delivery

Advanced Search

178
Use the form above to filter the list of products displayed or search for text using the Search by SmartText™ box, then click Apply to narrow the list of products shown. Note: the search box searches multiple text fields, including those not visible until you click the See Advanced Data View button.
Product IDSampleOriginMatrixVial (ml)Vial (ml)QuantityPriceAgeGenderEthnicityStorage TempSample DateTest 1Test Data 1Test Data 1Sample Detail 1Test 2Test Data 2Test 3Test Data 3Sample Detail 3Product DetailsPriceAdditional Information 1Additional Data 1Additional Information 2Additional Data 2Additional Detail 2Additional Information 3Additional Data 3Additional Information 4Additional Data 4Additional Information 5Additional Data 5Additional Information 6Additional Data 6Additional Information 7Additional Data 7ICD10 codes
DLS15-14151MethotrexateUSANa Heparin1.51.501.00$75.0066MWhite<-70C02-Oct-15Roche cobas c 502 Analyzer0.05umol/L0.05 umol/LMethotrexate$75.00C85.80
DLS15-14152MethotrexateUSANa Heparin1.51.501.00$75.0060FWhite<-70C02-Oct-15Roche cobas c 502 Analyzer0.11umol/L0.11 umol/LMethotrexate$75.00C91.00
DLS15-14184MethotrexateUSANa Heparin1.51.501.00$75.0062MWhite<-70C11-Oct-15Roche cobas c 502 Analyzer0.11umol/L0.11 umol/LMethotrexate$75.00C85.90
DLS15-14229MethotrexateUSANa Heparin1.51.501.00$75.0039MWhite<-70C15-Oct-15Roche cobas c 502 Analyzer0.16umol/L0.16 umol/LMethotrexate$75.00C41.9
DLS15-14230MethotrexateUSANa Heparin1.51.501.00$75.0039MWhite<-70C15-Oct-15Roche cobas c 502 Analyzer0.13umol/L0.13 umol/LMethotrexate$75.00C41.9
DLS15-14232MethotrexateUSANa Heparin1.51.501.00$75.0039MWhite<-70C16-Oct-15Roche cobas c 502 Analyzer0.09umol/L0.09 umol/LMethotrexate$75.00C41.9
DLS15-14233MethotrexateUSANa Heparin1.51.501.00$75.0063FWhite<-70C16-Oct-15Roche cobas c 502 Analyzer0.05umol/L0.05 umol/LMethotrexate$75.00C83.30
DLS15-14251MethotrexateUSANa Heparin1.51.501.00$75.0039MWhite<-70C20-Oct-15Roche cobas c 502 Analyzer5.50umol/L5.50 umol/LMethotrexate$75.00C41.9
DLS15-17953MethotrexateUSAK2 EDTA Plasma1.251.251.00$75.0062MWhite<-70C24-Dec-15Roche cobas c 502 Analyzer6.9umol/L6.9 umol/LMethotrexate$75.00C85.90 K21.9 D75.89
DLS15-08688MethotrexateUSAL. Heparin Plasma11.001.00$75.0019FWhite<-70C18-May-16Roche cobas c 502 Analyzer19umol/L19 umol/LMethotrexate$75.00C78.00 E44.0 D70.9
DLS15-08783MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0018MAsian<-70C31-May-16Roche cobas c 502 Analyzer7.2umol/L7.2 umol/LMethotrexate$75.00M25.862 C41.9 D70.9
DLS16-31329MethotrexateUSAL. Heparin Plasma11.001.00$75.0014FBlack<-70C21-Jun-16Roche cobas c 502 Analyzer7.1umol/L7.1 umol/LMethotrexate$75.00C40.22 R50.9 C41.9
DLS16-31461MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0018MAsian<-70C09-Jul-16Roche cobas c 502 Analyzer7.8umol/L7.8 umol/LMethotrexate$75.00C41.9 D70.9 K12.31
DLS16-23867-SMethotrexateRussiaSerum11.007.00$150.0076FWhite<-70C07-Jul-16Abbott TDx FLx1.87ug/mL1.87 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage IV; T3N1M1G324-Jun-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 per day for 20 years Date of Initial Primary Tumor Diagnosis19-Jun-16Site of Primary TumorCervixSite of MetastasisBladderHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23876-SMethotrexateRussiaSerum11.0010.00$150.0061MWhite<-70C04-Jul-16Abbott TDx FLx0.67ug/mL0.67 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma, T-Cell LymphomaStagingStage IV; Grade G229-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 20 years Date of Initial Primary Tumor Diagnosis28-May-16Site of Primary TumorRegional Nodes, MediastinumSite of MetastasisBone Marrow, LiverHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23876-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0061MWhite<-70C04-Jul-16Abbott TDx FLx0.67ug/mL0.67 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma, T-Cell LymphomaStagingStage IV; Grade G229-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 20 years Date of Initial Primary Tumor Diagnosis28-May-16Site of Primary TumorRegional Nodes, MediastinumSite of MetastasisBone Marrow, LiverHistory of Benign Disease Prior to Cancer DiagnosisNoCurrent MedicationsNone
DLS16-23878-SMethotrexateRussiaSerum11.0010.00$150.0030FWhite<-70C25-Jul-16Abbott TDx FLx2.02ug/mL2.02 ug/mLMethotrexateClinical DiagnosisGestational Trophoblastic Neoplasia (C58)StagingStage I; T1N0M0G311-Jul-16$150.00Menopausal StatusPreSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis15-Jun-16Site of Primary TumorUterusSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23878-LHMethotrexateRussiaL. Heparin Plasma1.51.501.00$150.0030FWhite<-70C25-Jul-16Abbott TDx FLx2.02ug/mL2.02 ug/mLMethotrexateClinical DiagnosisGestational Trophoblastic Neoplasia (C58)StagingStage I; T1N0M0G311-Jul-16$150.00Menopausal StatusPreSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis15-Jun-16Site of Primary TumorUterusSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23879-SMethotrexateRussiaSerum11.007.00$150.0062FWhite<-70C23-Jun-16Abbott TDx FLx2.53ug/mL2.53 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage III; Grade G212-Feb-11$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis8-Feb-11Site of Primary TumorMediastinum Site of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer DiagnosisNoCurrent MedicationsNone
DLS16-23879-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0062FWhite<-70C23-Jun-16Abbott TDx FLx2.53ug/mL2.53 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage III; Grade G212-Feb-11$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis8-Feb-11Site of Primary TumorMediastinum Site of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer DiagnosisNo Current MedicationsNone
DLS16-23884-SMethotrexateRussiaSerum11.009.00$150.0054MWhite<-70C10-Jun-16Abbott TDx FLx0.40ug/mL0.40 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage IV; Grade G214-May-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer15-20 per day for 20 years Date of Initial Primary Tumor Diagnosis11-May-16Site of Primary TumorBone MarrowSite of MetastasisMediastinum, Liver, Central Nervous SystemHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23884-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0054MWhite<-70C10-Jun-16Abbott TDx FLx0.40ug/mL0.40 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphomaStagingStage IV; Grade G214-May-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer15-20 per day for 20 years Date of Initial Primary Tumor Diagnosis11-May-16Site of Primary TumorBone MarrowSite of MetastasisMediastinum, Liver, Central Nervous SystemHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23887-SMethotrexateRussiaSerum11.006.00$150.0065FWhite<-70C26-Jul-16Abbott TDx FLx0.10ug/mL0.10 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N1M0G211-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis7-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Ondansetron
DLS16-23887-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0065FWhite<-70C26-Jul-16Abbott TDx FLx0.10ug/mL0.10 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N1M0G211-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer8-10 per day for 30 years Date of Initial Primary Tumor Diagnosis7-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Ondansetron
DLS16-23888-SMethotrexateRussiaSerum11.008.00$150.0062FWhite<-70C05-Jul-16Abbott TDx FLx5.14ug/mL5.14 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N2M0G326-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 15-17 years Date of Initial Primary Tumor Diagnosis18-May-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsCisplatin; Bleomycin; Fluorouracil; Palonosetron
DLS16-23892-SMethotrexateRussiaSerum11.008.00$150.0069FWhite<-70C12-Aug-16Abbott TDx FLx0.08ug/mL0.08 ug/mLMethotrexateClinical DiagnosisEndometrial Adenocarcinoma (C54)StagingStage III; T3N1M0G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis18-Jun-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23893-SMethotrexateRussiaSerum11.008.00$150.0064FWhite<-70C15-Jul-16Abbott TDx FLx3.16ug/mL3.16 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G314-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 20 years Date of Initial Primary Tumor Diagnosis28-Apr-15Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of Benign Disease Prior to Cancer DiagnosisYes Current MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23893-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0064FWhite<-70C15-Jul-16Abbott TDx FLx3.16ug/mL3.16 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G314-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 20 years Date of Initial Primary Tumor Diagnosis28-Apr-15Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of Benign Disease Prior to Cancer Diagnosis Yes Current MedicationsEndoxan; Fluorouracil; Ondansetron
DLS16-23894-SMethotrexateRussiaSerum11.0010.00$150.0068FWhite<-70C17-Jun-16Abbott TDx FLx3.33ug/mL3.33 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N1M0G217-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 30 years Date of Initial Primary Tumor Diagnosis10-May-16Site of Primary TumorOvarySite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Methotrexate; Fluorouracil
DLS16-23894-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0068FWhite<-70C17-Jun-16Abbott TDx FLx3.33ug/mL3.33 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N1M0G217-May-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 30 years Date of Initial Primary Tumor Diagnosis10-May-16Site of Primary TumorOvarySite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Methotrexate; Fluorouracil
DLS16-23903-SMethotrexateRussiaSerum11.003.00$150.0070FWhite<-70C11-Jul-16Abbott TDx FLx2.76ug/mL2.76 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N2M0G313-Jun-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 40 years Date of Initial Primary Tumor Diagnosis29-May-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23903-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0070FWhite<-70C11-Jul-16Abbott TDx FLx2.76ug/mL2.76 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage III; T3N2M0G313-Jun-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 per day for 40 years Date of Initial Primary Tumor Diagnosis29-May-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23904-SMethotrexateRussiaSerum11.009.00$150.0072FWhite<-70C07-Jun-16Abbott TDx FLx2.51ug/mL2.51 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma (DLBCL)StagingStage IV; Grade G229-Nov-12$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 50 years Date of Initial Primary Tumor Diagnosis24-Nov-12Site of Primary TumorRegional (Axillary) NodeSite of MetastasisLiver, Bone MarrowHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23904-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0072FWhite<-70C07-Jun-16Abbott TDx FLx2.51ug/mL2.51 ug/mLMethotrexateClinical DiagnosisNon-Hodgkin lymphoma (DLBCL)StagingStage IV; Grade G229-Nov-12$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 50 years Date of Initial Primary Tumor Diagnosis24-Nov-12Site of Primary TumorRegional (Axillary) NodeSite of MetastasisLiver, Bone MarrowHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsNone
DLS16-23906-SMethotrexateRussiaSerum11.0011.00$150.0041FWhite<-70C15-Jun-16Abbott TDx FLx3.53ug/mL3.53 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage IV; T3N1M1G216-Apr-16$150.00Menopausal StatusPreSmoking HistoryFormer5-10 per day for 10 years Date of Initial Primary Tumor Diagnosis2-Mar-16Site of Primary TumorCervixSite of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsBleomycin; Fluorouracil
DLS16-23906-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0041FWhite<-70C15-Jun-16Abbott TDx FLx3.53ug/mL3.53 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage IV; T3N1M1G216-Apr-16$150.00Menopausal StatusPreSmoking HistoryFormer5-10 per day for 10 years Date of Initial Primary Tumor Diagnosis2-Mar-16Site of Primary TumorCervixSite of MetastasisRegional NodesHistory of Benign Disease Prior to Cancer Diagnosis No Current MedicationsBleomycin; Fluorouracil
DLS16-23907-SMethotrexateRussiaSerum11.006.00$150.0051FWhite<-70C23-Jun-16Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T2N1M0G214-May-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis3-Apr-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23907-LHMethotrexateRussiaL. Heparin Plasma1.51.501.00$150.0051FWhite<-70C23-Jun-16Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T2N1M0G214-May-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis3-Apr-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsBleomycin; Fluorouracil
DLS16-23914-SMethotrexateRussiaSerum11.0010.00$150.0061FWhite<-70C15-Jun-16Abbott TDx FLx0.04ug/mL0.04 ug/mLMethotrexateClinical DiagnosisCorpus Uteri Cancer (C54)StagingStage III; T3N1M0G219-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 25 years Date of Initial Primary Tumor Diagnosis28-Apr-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Fluorouracil
DLS16-23914-LHMethotrexateRussiaL. Heparin Plasma1.51.501.00$150.0061FWhite<-70C15-Jun-16Abbott TDx FLx0.04ug/mL0.04 ug/mLMethotrexateClinical DiagnosisCorpus Uteri Cancer (C54)StagingStage III; T3N1M0G219-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-12 per day for 25 years Date of Initial Primary Tumor Diagnosis28-Apr-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsEndoxan; Fluorouracil
DLS16-23882-SMethotrexateRussiaSerum11.007.00$150.0044FAsian<-70C08-Sep-16Abbott TDx FLx2.58ug/mL2.58 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N2M0G317-Aug-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis25-Jul-16Site of Primary TumorOvary (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23882-LHMethotrexateRussiaL. Heparin Plasma1.251.251.00$150.0044FAsian<-70C08-Sep-16Abbott TDx FLx2.58ug/mL2.58 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage III; T3N2M0G317-Aug-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis25-Jul-16Site of Primary TumorOvary (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23883-SMethotrexateRussiaSerum11.004.00$150.0056FWhite<-70C14-Sep-16Abbott TDx FLx2.03ug/mL2.03 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage II; T2N0M0G330-Aug-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer5-10 per day for 25 years Date of Initial Primary Tumor Diagnosis29-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23883-LHMethotrexateRussiaL. Heparin Plasma1.251.251.00$150.0056FWhite<-70C14-Sep-16Abbott TDx FLx2.03ug/mL2.03 ug/mLMethotrexateClinical DiagnosisCervical Cancer (C53)StagingStage II; T2N0M0G330-Aug-16$150.00Menopausal StatusMenopauseSmoking HistoryFormer5-10 per day for 25 years Date of Initial Primary Tumor Diagnosis29-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23886-SMethotrexateRussiaSerum11.0011.00$150.0058FAsian<-70C06-Oct-16Abbott TDx FLx1.16ug/mL1.16 ug/mLMethotrexateClinical DiagnosisEndometrial Cancer (C54)StagingStage III; T3NXM0G24-Sep-16$150.00Menopausal StatusPostSmoking HistoryFormer5-8 per day for 5 years Date of Initial Primary Tumor Diagnosis18-Aug-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23886-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0058FAsian<-70C06-Oct-16Abbott TDx FLx1.16ug/mL1.16 ug/mLMethotrexateClinical DiagnosisEndometrial Cancer (C54)StagingStage III; T3NXM0G24-Sep-16$150.00Menopausal StatusPostSmoking HistoryFormer5-8 per day for 5 years Date of Initial Primary Tumor Diagnosis18-Aug-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23895-SMethotrexateRussiaSerum11.007.00$150.0039FWhite<-70C12-Sep-16Abbott TDx FLx2.43ug/mL2.43 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage II; T2NXM0G319-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent8-10 per day for 10 years Date of Initial Primary Tumor Diagnosis20-Jul-16Site of Primary TumorOvary (left)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23895-LHMethotrexateRussiaL. Heparin Plasma1.251.251.00$150.0039FWhite<-70C12-Sep-16Abbott TDx FLx2.43ug/mL2.43 ug/mLMethotrexateClinical DiagnosisOvarian Cancer (C56)StagingStage II; T2NXM0G319-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent8-10 per day for 10 years Date of Initial Primary Tumor Diagnosis20-Jul-16Site of Primary TumorOvary (left)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23908-SMethotrexateRussiaSerum11.0012.00$150.0049FAsian<-70C05-Sep-16Abbott TDx FLx1.42ug/mL1.42 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T3N1M0G38-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent5-8 per day for 20 years Date of Initial Primary Tumor Diagnosis2-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23908-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0049FAsian<-70C05-Sep-16Abbott TDx FLx1.42ug/mL1.42 ug/mLMethotrexateClinical DiagnosisCancer Colli Uteri (C53)StagingStage III; T3N1M0G38-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent5-8 per day for 20 years Date of Initial Primary Tumor Diagnosis2-Jul-16Site of Primary TumorCervixSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23910-SMethotrexateRussiaSerum11.003.00$150.0064MWhite<-70C13-Sep-16Abbott TDx FLx0.52ug/mL0.52 ug/mLMethotrexateClinical DiagnosisNSCLCStagingStage III; T3NXM0G330-Aug-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 per day for 30 years Date of Initial Primary Tumor Diagnosis4-Aug-16Site of Primary TumorLung (right)Site of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23911-SMethotrexateRussiaSerum11.005.00$150.0067FWhite<-70C16-Sep-16Abbott TDx FLx0.52ug/mL0.52 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G31-Sep-16$150.00Menopausal StatusPostSmoking HistoryCurrent8-10 per day for 40 years Date of Initial Primary Tumor Diagnosis11-Jul-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23911-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0067FWhite<-70C16-Sep-16Abbott TDx FLx0.52ug/mL0.52 ug/mLMethotrexateClinical DiagnosisCancer Corpus Uteri (C54)StagingStage III; T3N1M0G31-Sep-16$150.00Menopausal StatusPostSmoking HistoryCurrent8-10 per day for 40 years Date of Initial Primary Tumor Diagnosis11-Jul-16Site of Primary TumorCorpus UteriSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS14-32074MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0051FWhite<-70C15-Jun-16Roche cobas c 502 Analyzer1.15umol/L1.15 umol/LMethotrexate$75.00C85.81 R00.1 H26.9
DLS14-32078MethotrexateUSAK2 EDTA Plasma1.251.251.00$75.0057FWhite<-70C11-Jun-16Roche cobas c 502 Analyzer1.05umol/L1.05 umol/LMethotrexate$75.00A41.52 D49.6 N60.19
DLS16-30887MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0060FWhite<-70C23-Jun-16Roche cobas c 502 Analyzer2.8umol/L2.8 umol/LMethotrexate$75.00G93.6 K91.1 F32.9
DLS16-31455MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0051FWhite<-70C13-Jul-16Roche cobas c 502 Analyzer1.03umol/L1.03 umol/LMethotrexate$75.00C85.81 R00.1 H26.9
DLS16-32205MethotrexateUSAL. Heparin Plasma11.001.00$75.0013MWhite<-70C10-Sep-16Roche cobas c 502 Analyzer1.01umol/L1.01 umol/LMethotrexate$75.00F80.89 C91.00 L02.91
DLS15-08788MethotrexateUSAL. Heparin Plasma11.001.00$75.0014FBlack<-70C26-May-16Roche cobas c 502 Analyzer0.21umol/L0.21 umol/LMethotrexate$75.00C40.00 R50.9 C41.9
DLS17-017005MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0052FWhite<-70C14-May-17Roche cobas c 502 Analyzer0.14umol/L0.14 umol/LMethotrexate$75.00D64.81 R11.2 C83.38 C83.30 K59.03 K21.9 E78.5 E03.9 E03.8 M54.5 I80.9
DLS16-23855-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0039MWhite<-70C30-Sep-16Abbott TDx FLx0.36ug/mL0.36 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G223-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 8-10 years Date of Initial Primary Tumor Diagnosis19-May-16Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System, Bone MarrowWas Subject on previously on ChemotherapyYes 24-May-2016 to 29-May-2016 and 11-Jul-2016 to 16-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23855-SMethotrexateRussiaSerum11.0010.00$150.0039MWhite<-70C30-Sep-16Abbott TDx FLx0.36ug/mL0.36 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G223-May-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 8-10 years Date of Initial Primary Tumor Diagnosis19-May-16Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System, Bone MarrowWas Subject on previously on ChemotherapyYes 24-May-2016 to 29-May-2016 and 11-Jul-2016 to 16-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23860-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0056MAsian<-70C26-Oct-16Abbott TDx FLx0.30ug/mL0.30 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage III; Grade G316-Jan-15$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day, 10 years Date of Initial Primary Tumor Diagnosis12-Jan-15Site of Primary TumorRegional (Axillary) NodesSite of MetastasisLiver, Mediastinal NodesWas Subject on previously on ChemotherapyYes Jan-2015 - Jul-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23860-SMethotrexateRussiaSerum11.008.00$150.0056MAsian<-70C26-Oct-16Abbott TDx FLx0.30ug/mL0.30 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage III Grade G316-Jan-15$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 10 years Date of Initial Primary Tumor Diagnosis12-Jan-15Site of Primary TumorRegional (Axillary) NodesSite of MetastasisLiver, Mediastinal NodesWas Subject on previously on ChemotherapyYes Jan-2015 - Jul-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23875-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0051MWhite<-70C03-Aug-16Abbott TDx FLx0.20ug/mL0.20 ug/mLMethotrexateClinical DiagnosisT-cell Acute Lymphoblastic Leukemia (T-ALL)StagingStage IV1-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis31-May-16Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block (ALL 2009 and since 3-Jun-2016), Current ChemotherapyHD-MTX
DLS16-23875-SMethotrexateRussiaSerum11.008.00$150.0051MWhite<-70C03-Aug-16Abbott TDx FLx0.20ug/mL0.20 ug/mLMethotrexateClinical DiagnosisT-cell Acute Lymphoblastic Leukemia (T-ALL)StagingStage IV1-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis31-May-16Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block (ALL 2009 and since 3-Jun-2016), Current ChemotherapyHD-MTX
DLS16-23877-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0056MWhite<-70C26-Aug-16Abbott TDx FLx0.13ug/mL0.13 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 8-15 cigs/day 10 years Date of Initial Primary Tumor Diagnosis20-Jun-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System, Paraaortal NodesWas Subject on previously on ChemotherapyYes 24-Jun-2016 to 29-Jun-2016 Hyper CVADCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23877-SMethotrexateRussiaSerum11.006.00$150.0056MWhite<-70C26-Aug-16Abbott TDx FLx0.13ug/mL0.13 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 8-15 cigs/day 10 years Date of Initial Primary Tumor Diagnosis20-Jun-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System, Paraaortal NodesWas Subject on previously on ChemotherapyYes 24-Jun-2016 to 29-Jun-2016 Hyper CVADCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23880-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0062FAsian<-70C04-Oct-16Abbott TDx FLx0.10ug/mL0.10 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G2 17-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis12-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System Was Subject on previously on ChemotherapyYes 17-Jul-2016 to 22-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23880-SMethotrexateRussiaSerum11.006.00$150.0062FAsian<-70C04-Oct-16Abbott TDx FLx0.10ug/mL0.10 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G2 17-Jul-16$150.00Menopausal StatusPostSmoking HistoryNoneN/A Date of Initial Primary Tumor Diagnosis12-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Central Nervous System Was Subject on previously on ChemotherapyYes 17-Jul-2016 to 22-Jul-2016 Hyper CVADCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23890-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0043MWhite<-70C28-Jul-16Abbott TDx FLx0.91ug/mL0.91 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G314-Jun-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 20 years Date of Initial Primary Tumor Diagnosis10-Jun-16Site of Primary TumorCentral Nervous System Site of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyInduction block (since 14-Jun-2016), Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23890-SMethotrexateRussiaSerum11.009.00$150.0043MWhite<-70C28-Jul-16Abbott TDx FLx0.91ug/mL0.91 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G314-Jun-16$150.00Menopausal StatusN/ASmoking HistoryCurrent10-15 cigs/day 20 years Date of Initial Primary Tumor Diagnosis10-Jun-16Site of Primary TumorCentral Nervous System Site of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyInduction block (since 14-Jun-2016), Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23897-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0060MWhite<-70C08-Sep-16Abbott TDx FLx0.54ug/mL0.54 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G38-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 35 years Date of Initial Primary Tumor Diagnosis4-Jun-16Site of Primary TumorRegional Nodes (Submandibular, Supraclavicular)Site of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 9-Jun-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23897-SMethotrexateRussiaSerum11.008.00$150.0060MWhite<-70C08-Sep-16Abbott TDx FLx0.54ug/mL0.54 ug/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G38-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 35 years Date of Initial Primary Tumor Diagnosis4-Jun-16Site of Primary TumorRegional Nodes (Submandibular, Supraclavicular)Site of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 9-Jun-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23899-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0044MWhite<-70C28-Sep-16Abbott TDx FLx1.10ug/mL1.10 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G215-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer 5-15 cigs/day 15 years Date of Initial Primary Tumor Diagnosis10-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyYes 15-Jul-2016 to 20-Jul-2016 1 cycle R-CHOP 8-Aug-2016 to 14-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23899-SMethotrexateRussiaSerum11.004.00$150.0044MWhite<-70C28-Sep-16Abbott TDx FLx1.10ug/mL1.10 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G215-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-15 cigs/day 15 years Date of Initial Primary Tumor Diagnosis10-Jul-16Site of Primary TumorRegional NodesSite of MetastasisLiver, Mediastinal Nodes, Bone MarrowWas Subject on previously on ChemotherapyYes 15-Jul-2016 to 20-Jul-2016 1 cycle R-CHOP 8-Aug-2016 to 14-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23909-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0058MWhite<-70C07-Oct-16Abbott TDx FLx0.77ug/mL0.77 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL)StagingStage IV14-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis12-Aug-16Site of Primary TumorBone MarrowSite of MetastasisTesticular, LiverWas Subject on previously on ChemotherapyYes 15-Aug-2016 to 20-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23909-SMethotrexateRussiaSerum11.009.00$150.0058MWhite<-70C07-Oct-16Abbott TDx FLx0.77ug/mL0.77 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL)StagingStage IV14-Aug-16$150.00Menopausal StatusN/ASmoking HistoryCurrent 10-15 cigs/day 25 years Date of Initial Primary Tumor Diagnosis12-Aug-16Site of Primary TumorBone MarrowSite of MetastasisTesticular, LiverWas Subject on previously on ChemotherapyYes 15-Aug-2016 to 20-Aug-2016 Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23913-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0058MWhite<-70C19-Aug-16Abbott TDx FLx0.56ug/mL0.56 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G28-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 30 years Date of Initial Primary Tumor Diagnosis6-Jun-16Site of Primary TumorRegional Nodes (Axillary, Subclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 15-Jun-2016 2 cycles R-CHOP Current ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23913-SMethotrexateRussiaSerum11.006.00$150.0058MWhite<-70C19-Aug-16Abbott TDx FLx0.56ug/mL0.56 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell LymphomaStagingStage IV; Grade G28-Jun-16$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 30 years Date of Initial Primary Tumor Diagnosis6-Jun-16Site of Primary TumorRegional Nodes (Axillary, Subclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 15-Jun-2016 2 cycles R-CHOP Current ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23862-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0049MWhite<-70C21-Nov-16Abbott TDx FLx0.45uU/mL0.45 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G26-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer 13-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis3-Oct-2016Site of Primary TumorMediastinal NodesSite of MetastasisBone Marrow Was Subject on previously on ChemotherapyYes, 7-Oct-2016 to 13-Oct Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23862-SMethotrexateRussiaSerum11.006.00$150.0049MWhite<-70C21-Nov-16Abbott TDx FLx0.45uU/mL0.45 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G26-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer13-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis3-Oct-2016Site of Primary TumorMediastinal NodesSite of MetastasisBone Marrow Was Subject on previously on ChemotherapyYes, 7-Oct-2016 to 13-Oct Hyper CVADCurrent ChemotherapyHD-MTX
DLS16-23865-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0052MWhite<-70C22-Dec-16Abbott TDx FLx0.11uU/mL0.11 uU/mLMethotrexateClinical DiagnosisAnaplastic NHLStagingStage IV; Grade G22-Nov-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis26-Oct-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 3-Nov-2016 1 cycle R-CHOPCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23865-SMethotrexateRussiaSerum11.007.00$150.0052MWhite<-70C22-Dec-16Abbott TDx FLx0.11uU/mL0.11 uU/mLMethotrexateClinical DiagnosisAnaplastic NHLStagingStage IV; Grade G22-Nov-16$150.00Menopausal StatusN/ASmoking HistoryFormer10-20 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis26-Oct-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisBone Marrow, LiverWas Subject on previously on ChemotherapyYes since 3-Nov-2016 1 cycle R-CHOPCurrent ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23866-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0050MWhite<-70C18-Nov-16Abbott TDx FLx0.10uU/mL0.10 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G315-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-10 cigs/day for 10 yearsDate of Initial Primary Tumor Diagnosis12-Jul-2016Site of Primary TumorCentral Nervous System (isolated)Site of MetastasisN/AWas Subject on previously on ChemotherapyRituximab and Ara-C since 15-Jul-2016Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23866-SMethotrexateRussiaSerum11.007.00$150.0050MWhite<-70C18-Nov-16Abbott TDx FLx0.10uU/mL0.10 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G315-Jul-16$150.00Menopausal StatusN/ASmoking HistoryFormer5-10 cigs/day for 10 yearsDate of Initial Primary Tumor Diagnosis12-Jul-2016Site of Primary TumorCentral Nervous System (isolated)Site of MetastasisN/AWas Subject on previously on ChemotherapyRituximab and Ara-C since 15-Jul-2016Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23871-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0049MAsian<-70C22-Dec-16Abbott TDx FLx0.38uU/mL0.38 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV17-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer15-20 cigs/day for 17-20 yearsDate of Initial Primary Tumor Diagnosis14-Oct-2016Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 17-Oct-2016), Current ChemotherapyHD-MTX
DLS16-23871-SMethotrexateRussiaSerum11.0011.00$150.0049MAsian<-70C22-Dec-16Abbott TDx FLx0.38uU/mL0.38 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV17-Oct-16$150.00Menopausal StatusN/ASmoking HistoryFormer15-20 cigs/day for 17-20 yearsDate of Initial Primary Tumor Diagnosis14-Oct-2016Site of Primary TumorBone MarrowSite of MetastasisN/AWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 17-Oct-2016), Current ChemotherapyHD-MTX
DLS16-23881-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0064FWhite<-70C16-Sep-16Abbott TDx FLx0.67uU/mL0.67 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G323-Jun-16$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis23-Jun-2016Site of Primary TumorRegional Nodes (Inguinal ovary)Site of MetastasisRetroperitoneal Nodes, Spleen, Paraaortal NodesWas Subject on previously on ChemotherapyYes since 27-Jun-2016 2 cycles R-EPOCH Current ChemotherapyHD-MTX
DLS16-23881-SMethotrexateRussiaSerum11.005.00$150.0064FWhite<-70C16-Sep-16Abbott TDx FLx0.67uU/mL0.67 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G323-Jun-16$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis23-Jun-2016Site of Primary TumorRegional Nodes (Inguinal ovary)Site of MetastasisRetroperitoneal Nodes, Spleen, Paraaortal NodesWas Subject on previously on ChemotherapyYes since 27-Jun-2016 2 cycles R-EPOCH Current ChemotherapyHD-MTX
DLS16-23885-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0055MWhite<-70C21-Nov-16Abbott TDx FLx0.79uU/mL0.79 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (relapse)StagingStage III; Grade G218-May-15$150.00Menopausal StatusN/ASmoking HistoryFormer10-12 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis3-May-2015Site of Primary TumorRegional Nodes, Spleen (Supraclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 18-May-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23885-SMethotrexateRussiaSerum11.007.00$150.0055MWhite<-70C21-Nov-16Abbott TDx FLx0.79uU/mL0.79 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (relapse)StagingStage III; Grade G218-May-15$150.00Menopausal StatusN/ASmoking HistoryFormer10-12 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis3-May-2015Site of Primary TumorRegional Nodes, Spleen (Supraclavicular)Site of MetastasisN/AWas Subject on previously on ChemotherapyYes since 18-May-2015 6 cycles R-CHOPCurrent ChemotherapyHMA (HD-MTX, Ara-C)
DLS16-23889-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0064FWhite<-70C22-Jul-16Abbott TDx FLx0.81uU/mL0.81 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis19-Apr-2016Site of Primary TumorMediastinal NodesSite of MetastasisRegional Nodes, Bone Marrow, LiverWas Subject on previously on ChemotherapyYes since 25-May-2016 1 cycle R-EPOCH Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23889-SMethotrexateRussiaSerum11.007.00$150.0064FWhite<-70C22-Jul-16Abbott TDx FLx0.81uU/mL0.81 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell LymphomaStagingStage IV; Grade G324-May-16$150.00Menopausal StatusPostSmoking HistoryFormer10-15 cigs/day for 15 yearsDate of Initial Primary Tumor Diagnosis19-Apr-2016Site of Primary TumorMediastinal NodesSite of MetastasisRegional Nodes, Bone Marrow, LiverWas Subject on previously on ChemotherapyYes since 25-May-2016 1 cycle R-EPOCH Current ChemotherapyRMA (Rituximab,HD-MTX, Ara-C)
DLS16-23891-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0066FWhite<-70C07-Dec-16Abbott TDx FLx0.15uU/mL0.15 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (DBLCL)StagingStage III; Grade G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis11-Jul-2016Site of Primary TumorRegional Nodes, MediastinalSite of MetastasisRetroperitoneal Nodes, Spleen Was Subject on previously on ChemotherapyYes since 18-Jul-2016 6 cycles R-CHOPCurrent ChemotherapyHD-MTX
DLS16-23891-SMethotrexateRussiaSerum11.007.00$150.0066FWhite<-70C07-Dec-16Abbott TDx FLx0.15uU/mL0.15 uU/mLMethotrexateClinical DiagnosisNHL, B-Cell Lymphoma (DBLCL)StagingStage III; Grade G315-Jul-16$150.00Menopausal StatusPostSmoking HistoryFormer5-10 cigs/day for 20 yearsDate of Initial Primary Tumor Diagnosis11-Jul-2016Site of Primary TumorRegional Nodes, MediastinalSite of MetastasisRetroperitoneal Nodes, Spleen Was Subject on previously on ChemotherapyYes since 18-Jul-2016 6 cycles R-CHOPCurrent ChemotherapyHD-MTX
DLS16-23900-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0061MWhite<-70C29-Aug-16Abbott TDx FLx0.10uU/mL0.10 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (pre-B)StagingStage IV14-May-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis12-May-2016Site of Primary TumorBone MarrowSite of MetastasisLiver, Central Nervous SystemWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 15-May-2016), Current ChemotherapyHD-MTX
DLS16-23900-SMethotrexateRussiaSerum11.0010.00$150.0061MWhite<-70C29-Aug-16Abbott TDx FLx0.10uU/mL0.10 uU/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (pre-B)StagingStage IV14-May-16$150.00Menopausal StatusN/ASmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis12-May-2016Site of Primary TumorBone MarrowSite of MetastasisLiver, Central Nervous SystemWas Subject on previously on ChemotherapyInduction block A (ALL 2009 and since 15-May-2016), Current ChemotherapyHD-MTX
DLS16-23912-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0060FAsian<-70C15-Sep-16Abbott TDx FLx0.08uU/mL0.08 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell Lymphoma (relapse)StagingStage III; Grade G24-Apr-14$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis30-Mar-2014Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinum Was Subject on previously on ChemotherapyYes since 4-Apr-2014 6 cycles R-CHOP Current ChemotherapyHyper CVAD (HD-MTX)
DLS16-23912-SMethotrexateRussiaSerum11.003.00$150.0060FAsian<-70C15-Sep-16Abbott TDx FLx0.08uU/mL0.08 uU/mLMethotrexateClinical DiagnosisNHL, T-Cell Lymphoma (relapse)StagingStage III; Grade G24-Apr-14$150.00Menopausal StatusPostSmoking HistoryNoneN/ADate of Initial Primary Tumor Diagnosis30-Mar-2014Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinum Was Subject on previously on ChemotherapyYes since 4-Apr-2014 6 cycles R-CHOP Current ChemotherapyHyper CVAD (HD-MTX)
DLS17-017583MethotrexateUSAL. Heparin Plasma11.001.00$75.0015FBlack<-70C15-Jun-17Roche cobas c 502 Analyzer0.21umol/L0.21 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.18 G89.3
DLS17-017718MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0067MWhite<-70C25-Jun-17Roche cobas c 502 Analyzer0.1umol/L0.1 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 B02.29 M47.9 G62.9 G40.201 Z87.898 K59.01 E87.8 C83.30
DLS17-017719MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0067MWhite<-70C23-Jun-17Roche cobas c 502 Analyzer0.64umol/L0.64 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 B02.29 M47.9 G62.9 G40.201 Z87.898 K59.01 E87.8 C83.30
DLS17-022021MethotrexateUSAPlasma11.001.00$75.0052FU/A<-70C12-Aug-17Abbott FLX0.1umol/L0.1 umol/LMethotrexate$75.00
DLS17-022023MethotrexateUSAPlasma1.51.501.00$75.0052FU/A<-70C11-Aug-17Abbott FLX0.12umol/L0.12 umol/LMethotrexate$75.00
DLS17-022024MethotrexateUSAPlasma1.51.501.00$75.0052FU/A<-70C11-Aug-17Abbott FLX0.13umol/L0.13 umol/LMethotrexate$75.00
DLS16-23859-SMethotrexateRussiaSerum11.009.00$150.0058FWhite<-70C26-May-17Abbott TDx FLx2.9ug/mL2.9 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) T-cellStagingStage IV, Grade N/A23-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23859-LHMethotrexateRussiaL. Heparin Plasma11.003.00$150.0058FWhite<-70C26-May-17Abbott TDx FLx2.9ug/mL2.9 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) T-cellStagingStage IV, Grade N/A23-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23861-SMethotrexateRussiaSerum11.005.00$150.0058FWhite<-70C22-May-17Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) Pre-BStagingStage IV, Grade N/A9-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorBone MarrowSite of MetastasisLiver, SpleenHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23861-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0058FWhite<-70C22-May-17Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) Pre-BStagingStage IV, Grade N/A9-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorBone MarrowSite of MetastasisLiver, SpleenHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23864-SMethotrexateRussiaSerum11.005.00$150.0049FAsian<-70C19-Apr-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV, Grade G424-Feb-17$150.00Menopausal StatusPreSmoking HistoryFormer 5-10 cigs/day 15 yearsDate of Initial Primary Tumor Diagnosis18-Feb-2017Site of Primary TumorBone MarrowSite of MetastasisCentral Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23864-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0049FAsian<-70C19-Apr-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL) B-cellStagingStage IV, Grade G424-Feb-17$150.00Menopausal StatusPreSmoking HistoryFormer 5-10 cigs/day 15 yearsDate of Initial Primary Tumor Diagnosis18-Feb-2017Site of Primary TumorBone MarrowSite of MetastasisCentral Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23869-SMethotrexateRussiaSerum11.005.00$150.0067FWhite<-70C29-Apr-17Abbott TDx FLx0.08ug/mL0.08 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G326-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Jan-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23869-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0067FWhite<-70C29-Apr-17Abbott TDx FLx0.08ug/mL0.08 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G326-Apr-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Jan-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23870-SMethotrexateRussiaSerum11.006.00$150.0044MAsian<-70C14-Mar-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G41-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis12-Jan-2017Site of Primary TumorRegional Nodes (Mediastinal) Site of MetastasisSpleen, Bone Marrow, Central Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23870-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0044MAsian<-70C14-Mar-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G41-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 15-20 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis12-Jan-2017Site of Primary TumorRegional Nodes (Mediastinal) Site of MetastasisSpleen, Bone Marrow, Central Nervous System History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23872-SMethotrexateRussiaSerum11.004.00$150.0059FWhite<-70C12-Apr-17Abbott TDx FLx0.09ug/mL0.09 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G34-Mar-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis24-Oct-2015Site of Primary TumorMesenterial Nodes, StomachSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23872-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0059FWhite<-70C12-Apr-17Abbott TDx FLx0.09ug/mL0.09 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G34-Mar-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis24-Oct-2015Site of Primary TumorMesenterial Nodes, StomachSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23873-SMethotrexateRussiaSerum11.008.00$150.0049MWhite<-70C13-May-17Abbott TDx FLx0.18ug/mL0.18 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Lymphoma RelapseStagingStage IV, Grade G34-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 5-10 cigs/day 10 yearsDate of Initial Primary Tumor Diagnosis28-Jun-2016Site of Primary TumorRegional (Axillary) Nodes, SubclavicularSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23873-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0049MWhite<-70C13-May-17Abbott TDx FLx0.18ug/mL0.18 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Lymphoma RelapseStagingStage IV, Grade G34-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 5-10 cigs/day 10 yearsDate of Initial Primary Tumor Diagnosis28-Jun-2016Site of Primary TumorRegional (Axillary) Nodes, SubclavicularSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23896-SMethotrexateRussiaSerum11.007.00$150.0057FWhite<-70C24-Feb-17Abbott TDx FLx0.28ug/mL0.28 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell Mediastinal Lymphoma StagingStage IV, Grade G326-Jan-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis19-Jan-2017Site of Primary TumorMediastinal NodesSite of MetastasisBone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23896-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0057FWhite<-70C24-Feb-17Abbott TDx FLx0.28ug/mL0.28 ug/mLMethotrexateClinical DiagnosisNHL, B-Cell Mediastinal Lymphoma StagingStage IV, Grade G326-Jan-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis19-Jan-2017Site of Primary TumorMediastinal NodesSite of MetastasisBone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23901-SMethotrexateRussiaSerum11.008.00$150.0050FWhite<-70C10-Apr-17Abbott TDx FLx8.56ug/mL8.56 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G31-Mar-17$150.00Menopausal StatusPreSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Nov-2015Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinal Nodes, Involvement of Bone Marrow as a manifestation of relapseHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23901-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0050FWhite<-70C10-Apr-17Abbott TDx FLx8.56ug/mL8.56 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G31-Mar-17$150.00Menopausal StatusPreSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis4-Nov-2015Site of Primary TumorRegional (Axillary) NodesSite of MetastasisMediastinal Nodes, Involvement of Bone Marrow as a manifestation of relapseHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23905-SMethotrexateRussiaSerum11.004.00$150.0054FAsian<-70C13-Apr-17Abbott TDx FLx0.17ug/mL0.17 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Type progressionStagingStage IV, Grade G38-Feb-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Mar-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System (at the moment of progression)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23905-LHMethotrexateRussiaL. Heparin Plasma11.001.00$150.0054FAsian<-70C13-Apr-17Abbott TDx FLx0.17ug/mL0.17 ug/mLMethotrexateClinical DiagnosisNHL, Follicular Type progressionStagingStage IV, Grade G38-Feb-17$150.00Menopausal StatusPeriSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Mar-2016Site of Primary TumorRegional (Axillary) NodesSite of MetastasisCentral Nervous System (at the moment of progression)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23856-LHMethotrexateRussiaL. Heparin Plasma11.003.00$150.0054MAsian<-70C01-Apr-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G324-Dec-15$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis16-Dec-2015Site of Primary TumorStomach; Regional NodesSite of MetastasisLiver, Bone Marrow (on relapse)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23856-SMethotrexateRussiaSerum11.004.00$150.0054MAsian<-70C01-Apr-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G324-Dec-15$150.00Menopausal StatusN/ASmoking HistoryFormer 12-15 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis16-Dec-2015Site of Primary TumorStomach; Regional NodesSite of MetastasisLiver, Bone Marrow (on relapse)History of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23857-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0061FWhite<-70C08-Jul-17Abbott TDx FLx0.36ug/mL0.36 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G33-Jul-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Oct-2016Site of Primary TumorMediastinal LymphomaSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23857-SMethotrexateRussiaSerum11.008.00$150.0061FWhite<-70C08-Jul-17Abbott TDx FLx0.36ug/mL0.36 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+, RelapseStagingStage IV, Grade G33-Jul-17$150.00Menopausal StatusPostSmoking HistoryNoneDate of Initial Primary Tumor Diagnosis9-Oct-2016Site of Primary TumorMediastinal LymphomaSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23858-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0058MWhite<-70C05-Jun-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisBurkitt's lymphoma, CD20+StagingStage IV, Grade G32-Jun-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 25 yearsDate of Initial Primary Tumor Diagnosis29-May-2017Site of Primary TumorRegional Nodes (Mesenterial)Site of MetastasisSpleen; Liver; Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23858-SMethotrexateRussiaSerum11.007.00$150.0058MWhite<-70C05-Jun-17Abbott TDx FLx0.12ug/mL0.12 ug/mLMethotrexateClinical DiagnosisBurkitt's lymphoma, CD20+StagingStage IV, Grade G32-Jun-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-15 cigs/day 25 yearsDate of Initial Primary Tumor Diagnosis29-May-2017Site of Primary TumorRegional Nodes (Mesenterial)Site of MetastasisSpleen; Liver; Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23863-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0048MWhite<-70C17-Jun-17Abbott TDx FLx1.85ug/mL1.85 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL), B-II variant, CD20+StagingStage IV, Grade N/A2-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 15-17 yearsDate of Initial Primary Tumor Diagnosis25-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23863-SMethotrexateRussiaSerum11.005.00$150.0048MWhite<-70C17-Jun-17Abbott TDx FLx1.85ug/mL1.85 ug/mLMethotrexateClinical DiagnosisAcute Lymphoblastic Leukemia (ALL), B-II variant, CD20+StagingStage IV, Grade N/A2-May-17$150.00Menopausal StatusN/ASmoking HistoryFormer 10-20 cigs/day 15-17 yearsDate of Initial Primary Tumor Diagnosis25-Apr-2017Site of Primary TumorBone MarrowSite of MetastasisN/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23868-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0061MWhite<-70C25-May-17Abbott TDx FLx0.84ug/mL0.84 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G37-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 20-25 cigs/day 30 yearsDate of Initial Primary Tumor Diagnosis31-Jan-2017Site of Primary TumorGastric tumorSite of MetastasisRegional Nodes (Abdominals), Bone Marrow, LiverHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23868-SMethotrexateRussiaSerum11.003.00$150.0061MWhite<-70C25-May-17Abbott TDx FLx0.84ug/mL0.84 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G37-Feb-17$150.00Menopausal StatusN/ASmoking HistoryFormer 20-25 cigs/day 30 yearsDate of Initial Primary Tumor Diagnosis31-Jan-2017Site of Primary TumorGastric tumorSite of MetastasisRegional Nodes (Abdominals), Bone Marrow, LiverHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23874-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0036MWhite<-70C04-Jun-17Abbott TDx FLx0.08ug/mL0.08 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G417-Feb-17$150.00Menopausal StatusN/ASmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Feb-2017Site of Primary TumorRegional Nodes (Subclavicular)Site of MetastasisMediastinal Nodes, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23874-SMethotrexateRussiaSerum11.0010.00$150.0036MWhite<-70C04-Jun-17Abbott TDx FLx0.08ug/mL0.08 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G417-Feb-17$150.00Menopausal StatusN/ASmoking HistoryNoneDate of Initial Primary Tumor Diagnosis2-Feb-2017Site of Primary TumorRegional Nodes (Subclavicular)Site of MetastasisMediastinal Nodes, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23898-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0058FWhite<-70C25-Jun-17Abbott TDx FLx0.62ug/mL0.62 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G320-Jun-17$150.00Menopausal StatusPostSmoking HistoryFormer 5-10 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis14-Apr-2016Site of Primary TumorRegional (Cervical, Axillary) NodesSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23898-SMethotrexateRussiaSerum11.007.00$150.0058FWhite<-70C25-Jun-17Abbott TDx FLx0.62ug/mL0.62 ug/mLMethotrexateClinical DiagnosisAnaplastic NHL (relapse)StagingStage IV, Grade G320-Jun-17$150.00Menopausal StatusPostSmoking HistoryFormer 5-10 cigs/day 20 yearsDate of Initial Primary Tumor Diagnosis14-Apr-2016Site of Primary TumorRegional (Cervical, Axillary) NodesSite of MetastasisBone Marrow (on relapse); Primary N/AHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23902-LHMethotrexateRussiaL. Heparin Plasma11.002.00$150.0050MWhite<-70C14-Jun-17Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G310-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 12-18 cigs/day 15-20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorCentral Nervous SystemSite of MetastasisNasopharynx, Liver, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS16-23902-SMethotrexateRussiaSerum11.006.00$150.0050MWhite<-70C14-Jun-17Abbott TDx FLx0.11ug/mL0.11 ug/mLMethotrexateClinical DiagnosisNHL, DLBCL, CD20+ StagingStage IV, Grade G310-Mar-17$150.00Menopausal StatusN/ASmoking HistoryFormer 12-18 cigs/day 15-20 yearsDate of Initial Primary Tumor Diagnosis2-Mar-2017Site of Primary TumorCentral Nervous SystemSite of MetastasisNasopharynx, Liver, Bone MarrowHistory of benign disease prior to cancer diagnosisNoCurrent MedicationsNone
DLS17-018332MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0048MWhite<-70C03-Jul-17Roche cobas c 502 Analyzer0.35umol/L0.35 umol/LMethotrexate$75.00E03.9 R60.0 R11.2 I82.409 R53.1 K21.9 R52 D61.810 J90 C85.89 B34.8 T38.0X1A
DLS17-018958MethotrexateUSAL. Heparin Plasma11.001.00$75.0014FBlack<-70C23-Jul-17Roche cobas c 502 Analyzer0.3umol/L0.3 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.3 C41.9
DLS17-018960MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0068MWhite<-70C22-Jul-17Roche cobas c 502 Analyzer0.12umol/L0.12 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-018961MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0067MWhite<-70C22-Jul-17Roche cobas c 502 Analyzer0.15umol/L0.15 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-018962MethotrexateUSAL. Heparin Plasma11.001.00$75.0067MWhite<-70C21-Jul-17Roche cobas c 502 Analyzer0.21umol/L0.21 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-019431MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0062FWhite<-70C28-Jul-17Roche cobas c 502 Analyzer0.06umol/L0.06 umol/LMethotrexate$75.00D64.9 IMO0001 F19.20 M51.36 M51.37 M41.9 Z87.891 F99 M15.9 F34.1 J44.9 M54.9 G47.33 N20.0 F33.41
DLS17-020013MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0068MWhite<-70C12-Aug-17Roche cobas c 502 Analyzer0.11umol/L0.11 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020014MethotrexateUSAL. Heparin Plasma11.001.00$75.005FWhite<-70C12-Aug-17Roche cobas c 502 Analyzer0.09umol/L0.09 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020015MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0068MWhite<-70C11-Aug-17Roche cobas c 502 Analyzer0.13umol/L0.13 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020016MethotrexateUSAL. Heparin Plasma1.51.501.00$75.005FWhite<-70C11-Aug-17Roche cobas c 502 Analyzer0.38umol/L0.38 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020018MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0068MWhite<-70C10-Aug-17Roche cobas c 502 Analyzer0.17umol/L0.17 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-020102MethotrexateUSAL. Heparin Plasma11.001.00$75.0031MWhite<-70C18-Aug-17Roche cobas c 502 Analyzer0.11umol/L0.11 umol/LMethotrexate$75.00D70.9 C91.00
DLS17-020103MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0065FWhite<-70C17-Aug-17Roche cobas c 502 Analyzer0.12umol/L0.12 umol/LMethotrexate$75.00R56.9 J44.9 D84.9 K12.31 R60.0 D69.59 I82.403 G89.3 I87.2 M62.81 C83.30
DLS17-020177MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0067MWhite<-70C27-Aug-17Roche cobas c 502 Analyzer0.1umol/L0.1 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020178MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0067MWhite<-70C26-Aug-17Roche cobas c 502 Analyzer0.19umol/L0.19 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020179MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0064FWhite<-70C25-Aug-17Roche cobas c 502 Analyzer0.1umol/L0.1 umol/LMethotrexate$75.00J30.9 J45.909 R32 E78.5 D36.7 I05.9 Z51.11 D70.1 Z91.89 N39.0 E87.8 E44.0 K30 Z79.899
DLS17-020180MethotrexateUSAL. Heparin Plasma11.001.00$75.005FWhite<-70C24-Aug-17Roche cobas c 502 Analyzer0.27umol/L0.27 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-018331MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0059MWhite<-70C05-Jul-17Roche cobas c 502 Analyzer1.07umol/L1.07 umol/LMethotrexate$75.00Z91.89 C85.10 R11.2 C85.89 E87.8 Z91.09 R51 K21.9 E78.5 R26.89 C85.90 D86.9 G93.6
DLS17-018959MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0014FBlack<-70C22-Jul-17Roche cobas c 502 Analyzer9.6umol/L9.6 umol/LMethotrexate$75.00C40.22 C78.01 C78.02 C41.4 Z51.11 C79.51 M21.70 M84.362D M79.672 G89.3 C41.9
DLS17-018963MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0067MWhite<-70C20-Jul-17Roche cobas c 502 Analyzer0.5umol/L0.5 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-018964MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0068MWhite<-70C20-Jul-17Roche cobas c 502 Analyzer0.64umol/L0.64 umol/LMethotrexate$75.00I49.8 M48.06 M54.5 M72.9 R41.82 E78.5 Z51.11 Z86.79 M1A.9XX0 D72.829 K21.9 E87.8 Z79.899 I95.1 N17.9 B37.0 R61 K62.5 K64.8 R74.0 R50.9 R60.0
DLS17-018965MethotrexateUSAL. Heparin Plasma1.251.251.00$75.0067MWhite<-70C19-Jul-17Roche cobas c 502 Analyzer19umol/L19 umol/LMethotrexate$75.00C85.99 G57.00 G56.00 C85.80 M65.30 M47.9 G62.9 G40.201 Z87.898 R11.2 E87.8 C83.30
DLS17-020017MethotrexateUSAL. Heparin Plasma1.251.251.00$75.005FWhite<-70C10-Aug-17Roche cobas c 502 Analyzer1.03umol/L1.03 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020019MethotrexateUSAL. Heparin Plasma1.251.251.00$75.005FWhite<-70C10-Aug-17Roche cobas c 502 Analyzer66umol/L66 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020181MethotrexateUSAL. Heparin Plasma1.51.501.00$75.005FWhite<-70C23-Aug-17Roche cobas c 502 Analyzer71umol/L71 umol/LMethotrexate$75.00C91.00 Z51.11
DLS17-020240MethotrexateUSAL. Heparin Plasma11.001.00$75.0020MWhite<-70C29-Aug-17Roche cobas c 502 Analyzer0.92umol/L0.92 umol/LMethotrexate$75.00C83.50
DLS17-020241MethotrexateUSAL. Heparin Plasma1.51.501.00$75.0073FWhite<-70C29-Aug-17Roche cobas11.7umol/L11.7 umol/LMethotrexate$75.00R53.1 R00.2 R53.83 M60.9 E43 C85.10
DLS17-036150MethotrexateUSASerum1.501.00$75.0059MU/A<-70C08-Oct-17Beckman Coulter AU6800.07umol/LMethotrexate$75.00
DLS17-038459MethotrexateUSAL. Heparin Plasma1.001.00$75.0020MWhite<-70C01-Nov-17Roche cobas 5020.11umol/LMethotrexate$75.00E80.4 C85.89
DLS17-020585MethotrexateUSAL. Heparin Plasma1.251.00$75.0076MWhite<-70C03-Oct-17Roche cobas 5020.12umol/LMethotrexate$75.00C85.89
DLS17-038457MethotrexateUSAL. Heparin Plasma1.501.00$75.0035MWhite<-70C05-Nov-17Roche cobas 5020.18umol/LMethotrexate$75.00D49.6 H54.7 J98.59 H53.47 R44.1 Z51.11 E03.9 R52 R74.0 T45.1X1A
DLS17-038458MethotrexateUSAL. Heparin Plasma1.501.00$75.0035MWhite<-70C04-Nov-17Roche cobas 5020.19umol/LMethotrexate$75.00D49.6 H54.7 J98.59 H53.47 R44.1 Z51.11 E03.9 R52 R74.0 T45.1X1A
DLS17-020586MethotrexateUSAL. Heparin Plasma1.501.00$75.0076MWhite<-70C01-Oct-17Roche cobas 5020.23umol/LMethotrexate$75.00C85.89
DLS17-020587MethotrexateUSAL. Heparin Plasma1.501.00$75.0076MWhite<-70C30-Sep-17Roche cobas 5020.64umol/LMethotrexate$75.00C85.89
DLS17-038460MethotrexateUSAL. Heparin Plasma1.001.00$75.0020MWhite<-70C31-Oct-17Roche cobas 5020.75umol/LMethotrexate$75.00E80.4 C85.89
DLS17-020588MethotrexateUSAL. Heparin Plasma1.501.00$75.0076MWhite<-70C29-Sep-17Roche cobas 5022.00umol/LMethotrexate$75.00C85.89

Keep in mind that all the samples comprised in Magellan represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.

Please read carefully before purchasing:

Clinical specimens for research use only.

Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.

If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreasheets for a comprehensive review of all available samples: USA (805) 528-4341

These products are supplied without warranty for suitability for specific applications or analytical determinations.